October 2024

SEOUL, South Korea, Oct. 24, 2024 /PRNewswire/ — J INTS BIO, a pioneering biopharmaceutical company, has unveiled promising interim results from the Phase 1/2 clinical trial of its novel 4th-generation EGFR Tyrosine Kinase Inhibitor (TKI), JIN-A02, aimed at EGFR-mutated non-small cell lung can

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: